185 related articles for article (PubMed ID: 25268354)
1. Response-predictive gene expression profiling of glioma progenitor cells in vitro.
Moeckel S; Meyer K; Leukel P; Heudorfer F; Seliger C; Stangl C; Bogdahn U; Proescholdt M; Brawanski A; Vollmann-Zwerenz A; Riemenschneider MJ; Bosserhoff AK; Spang R; Hau P
PLoS One; 2014; 9(9):e108632. PubMed ID: 25268354
[TBL] [Abstract][Full Text] [Related]
2. Validation Study: Response-Predictive Gene Expression Profiling of Glioma Progenitor Cells In Vitro.
Moeckel S; Vollmann-Zwerenz A; Proescholdt M; Brawanski A; Riemenschneider MJ; Bogdahn U; Bosserhoff AK; Spang R; Hau P
PLoS One; 2016; 11(3):e0151312. PubMed ID: 26978262
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment.
Hatipoglu G; Hock SW; Weiss R; Fan Z; Sehm T; Ghoochani A; Buchfelder M; Savaskan NE; Eyüpoglu IY
Cancer Sci; 2015 Feb; 106(2):160-70. PubMed ID: 25458015
[TBL] [Abstract][Full Text] [Related]
4. Effects of transforming growth factor-β inhibitor on the proliferation of glioma stem/progenitor cell.
Zhang Q; Guo W; Di C; Lou M; Li H; Zhao Y
Pol J Pathol; 2017; 68(4):312-317. PubMed ID: 29517201
[TBL] [Abstract][Full Text] [Related]
5. ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma.
Jin Y; Bin ZQ; Qiang H; Liang C; Hua C; Jun D; Dong WA; Qing L
J Cancer Res Clin Oncol; 2009 Oct; 135(10):1369-76. PubMed ID: 19340456
[TBL] [Abstract][Full Text] [Related]
6. NDRG1 overexpressing gliomas are characterized by reduced tumor vascularization and resistance to antiangiogenic treatment.
Broggini T; Wüstner M; Harms C; Stange L; Blaes J; Thomé C; Harms U; Mueller S; Weiler M; Wick W; Vajkoczy P; Czabanka M
Cancer Lett; 2016 Oct; 380(2):568-576. PubMed ID: 26297987
[TBL] [Abstract][Full Text] [Related]
7. Significance of perivascular tumour cells defined by CD109 expression in progression of glioma.
Shiraki Y; Mii S; Enomoto A; Momota H; Han YP; Kato T; Ushida K; Kato A; Asai N; Murakumo Y; Aoki K; Suzuki H; Ohka F; Wakabayashi T; Todo T; Ogawa S; Natsume A; Takahashi M
J Pathol; 2017 Dec; 243(4):468-480. PubMed ID: 28888050
[TBL] [Abstract][Full Text] [Related]
8. Selective calcium sensitivity in immature glioma cancer stem cells.
Wee S; Niklasson M; Marinescu VD; Segerman A; Schmidt L; Hermansson A; Dirks P; Forsberg-Nilsson K; Westermark B; Uhrbom L; Linnarsson S; Nelander S; Andäng M
PLoS One; 2014; 9(12):e115698. PubMed ID: 25531110
[TBL] [Abstract][Full Text] [Related]
9. Glioma initiating cells form a differentiation niche via the induction of extracellular matrices and integrin αV.
Niibori-Nambu A; Midorikawa U; Mizuguchi S; Hide T; Nagai M; Komohara Y; Nagayama M; Hirayama M; Kobayashi D; Tsubota N; Takezaki T; Makino K; Nakamura H; Takeya M; Kuratsu J; Araki N
PLoS One; 2013; 8(5):e59558. PubMed ID: 23704872
[TBL] [Abstract][Full Text] [Related]
10. Isoliquiritigenin inhibits the proliferation and induces the differentiation of human glioma stem cells.
Lin Y; Sun H; Dang Y; Li Z
Oncol Rep; 2018 Feb; 39(2):687-694. PubMed ID: 29251326
[TBL] [Abstract][Full Text] [Related]
11. Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells.
Datta S; Sears T; Cortopassi G; Woolard K; Angelastro JM
Biomed Pharmacother; 2021 Jan; 133():111058. PubMed ID: 33378970
[TBL] [Abstract][Full Text] [Related]
12. Inhibitor of Apoptosis Proteins Determines Glioblastoma Stem-Like Cell Fate in an Oxygen-Dependent Manner.
Soubéran A; Cappaï J; Chocry M; Nuccio C; Raujol J; Colin C; Lafitte D; Kovacic H; Quillien V; Baeza-Kallee N; Rougon G; Figarella-Branger D; Tchoghandjian A
Stem Cells; 2019 Jun; 37(6):731-742. PubMed ID: 30920104
[TBL] [Abstract][Full Text] [Related]
13. GSK1838705A, an IGF-1R inhibitor, inhibits glioma cell proliferation and suppresses tumor growth in vivo.
Zhou X; Shen F; Ma P; Hui H; Pei S; Chen M; Wang Z; Zhou W; Jin B
Mol Med Rep; 2015 Oct; 12(4):5641-6. PubMed ID: 26238593
[TBL] [Abstract][Full Text] [Related]
14. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.
Saito N; Fu J; Zheng S; Yao J; Wang S; Liu DD; Yuan Y; Sulman EP; Lang FF; Colman H; Verhaak RG; Yung WK; Koul D
Stem Cells; 2014 Jan; 32(1):301-12. PubMed ID: 24038660
[TBL] [Abstract][Full Text] [Related]
15. Targeting glioma stem cells: a novel framework for brain tumors.
Binello E; Germano IM
Cancer Sci; 2011 Nov; 102(11):1958-66. PubMed ID: 21848914
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways.
Yang F; Jove V; Xin H; Hedvat M; Van Meter TE; Yu H
Mol Cancer Res; 2010 Jan; 8(1):35-45. PubMed ID: 20053726
[TBL] [Abstract][Full Text] [Related]
17. New advances of microRNAs in glioma stem cells, with special emphasis on aberrant methylation of microRNAs.
Zhao B; Bian EB; Li J; Li J
J Cell Physiol; 2014 Sep; 229(9):1141-7. PubMed ID: 24374932
[TBL] [Abstract][Full Text] [Related]
18. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
19. An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines.
Giannopoulou E; Dimitropoulos K; Argyriou AA; Koutras AK; Dimitrakopoulos F; Kalofonos HP
Invest New Drugs; 2010 Oct; 28(5):554-60. PubMed ID: 19603143
[TBL] [Abstract][Full Text] [Related]
20. TGM2 inhibition attenuates ID1 expression in CD44-high glioma-initiating cells.
Fu J; Yang QY; Sai K; Chen FR; Pang JC; Ng HK; Kwan AL; Chen ZP
Neuro Oncol; 2013 Oct; 15(10):1353-65. PubMed ID: 23877317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
